Letrozole Manx Healthcare

Letrozole, the active ingredient in Letrozole Manx Healthcare, is an aromatase inhibitor presented as an oral tablet for oral use. It is employed in the hormonal treatment of estrogen receptor‑positive breast cancer in postmenopausal women.

GNH USA supplies Letrozole Manx Healthcare as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The product is manufactured under EU GMP standards and distributed globally. Our supply chain ensures consistent quality and regulatory compliance across markets.

Letrozole is used in the management of hormone‑dependent breast cancer, targeting estrogen‑driven disease pathways.

- Estrogen receptor‑positive breast cancer in postmenopausal women: reduces tumor progression and improves disease control. - Adjuvant therapy for early‑stage ER+ breast cancer: lowers the risk of recurrence after surgery. - Metastatic breast cancer in postmenopausal women: helps control disease spread and prolongs survival.

Letrozole may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hot flashes: sudden feeling of warmth, often with sweating. - Joint and muscle pain: aching or stiffness in limbs. - Fatigue: persistent tiredness not relieved by rest. - Nausea: mild to moderate upset stomach. - Headache: pressure or throbbing pain. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe liver injury: jaundice, elevated enzymes. - Bone fracture: increased risk due to lowered estrogen. - Pulmonary embolism: sudden shortness of breath, chest pain. - Allergic reaction: rash, swelling, or anaphylaxis. - Elevated cholesterol: significant rise in lipid levels. - Cardiac arrhythmia: QT interval prolongation.

When prescribing Letrozole, clinicians should consider several safety measures and monitoring requirements.

- Pregnancy contraindication: avoid use in pregnant women (Category X). - Bone health monitoring: assess bone mineral density periodically. - Liver function: check hepatic enzymes before and during therapy. - Cardiovascular risk: evaluate history of thrombosis or heart disease. - Premenopausal status: not indicated for women who are not postmenopausal. - Store at below 25°C: keep in the original pack, protect from moisture.

Letrozole can affect the pharmacokinetics of other medicines; awareness of key interactions helps avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant estrogen therapy: may counteract letrozole's effect. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce plasma concentrations. - Tamoxifen: antagonistic action on estrogen pathways.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in anticoagulant effect. - Statins: possible alteration of lipid‑lowering efficacy. - Glucocorticoids: may enhance bone loss risk. - SSRIs: potential additive effect on dizziness. - Antihypertensives: monitor blood pressure changes.